1Dymedex Market Development Consulting, Strategic Market Assessment, GERD, 30 de outubro de 2014. Referências 1-3, 6-15, 22, 23, 25 e 34
2De Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030-6.
3Spechler S. et al. Barrett’s Esophagus. N Engl J Med 2014; 371:836-45.
4Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011;365:1375-83.
5Evans JA et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointestinal Endoscopy. 2012;27(6):1087-1094